Advertisement

Topics

Clinical observation of recombinant human endostatin in treating relapsed refractory multiple myeloma.

08:00 EDT 3rd August 2018 | BioPortfolio

Summary of "Clinical observation of recombinant human endostatin in treating relapsed refractory multiple myeloma."

Recombinant human endostatin (rhES) can inhibit multiple myeloma, while its clinical efficacy in treating relapsed refractory multiple myeloma (RRMM) has not been assessed. One hundred eleven RRMM patients were treated with four different regimens: combination of VD (velcade+dexamethasone) and rhES (n=25), Thalidomide (Tha) and VD (VTD, n=22) combination, rhES and conventional chemotherapy combination (n=32), and combination of conventional chemotherapy and Tha (n=32). Significant differences were found in progression-free survival (PFS) between rhES combination groups and conventional chemotherapy combination groups. No statistical difference was found in overall response rate, overall survival, or incidences of adverse effects. The combination of rhES with VD or conventional chemotherapy is active in patients with RRMM and prolongs the PFS to improve the quality of life. This article is protected by copyright. All rights reserved.

Affiliation

Journal Details

This article was published in the following journal.

Name: Clinical and experimental pharmacology & physiology
ISSN: 1440-1681
Pages:

Links

DeepDyve research library

PubMed Articles [31259 Associated PubMed Articles listed on BioPortfolio]

Progress in the problem of relapsed or refractory acute myeloid leukemia.

The majority of patients with acute myeloid leukemia (AML) die from disease recurrence and historically, treatment options in both the relapsed and refractory settings of this disease have been limite...

Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice.

Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice following daratumumab monotherapy have yet to be ...

Clinical Relevance of Genomic Changes in Recurrent Pediatric Solid Tumors.

Relapsed/refractory pediatric cancers show poor prognosis; however, their genomic patterns remain unknown. To investigate the genetic mechanisms of tumor relapse and therapy resistance, we characteriz...

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.

Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint pathway to evade immune surveillanc...

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.

Daratumumab is a human CD38-directed monoclonal antibody indicated for the treatment of relapsed and refractory multiple myeloma (MM).

Clinical Trials [14998 Associated Clinical Trials listed on BioPortfolio]

Endostatin in Treating Patients With Advanced Solid Tumors

RATIONALE: Endostatin may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of endostatin in treating patients who have adva...

Safety and Efficacy of Adenoviral Endostatin in the Treatment of Advanced Solid Tumor

The growth and metastasis of solid tumors are dependent on angiogenesis. Endostatin, the C-terminal proteolytic fragment of collagen XVIII, is an effective endogenous angiogenesis inhibito...

Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC)

Hepatocellular carcinoma(HCC) is a high malignancy cancer which progress rapidly , and the rates of morbidity and mortality is very high in China. Radiotherapy as a effective treatment is ...

A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC

We define refractory nasopharyngeal carcinoma as the following: recurrence with radiation brain injury after radiotherapy, recurrence after the second or more courses of radiotherapy, stan...

Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer.

To study safety and efficacy of intravenous pump of recombinant human endostatin combined with XELOX-treated and also investigate the potential value of CECs level for the prediction of PD...

Medical and Biotech [MESH] Definitions

Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.

The act of regarding attentively and studying facts and occurrences, gathering data through analyzing, measuring, and drawing conclusions, with the purpose of applying the observed information to theoretical assumptions. Observation as a scientific method in the acquisition of knowledge began in classical antiquity; in modern science and medicine its greatest application is facilitated by modern technology. Observation is one of the components of the research process.

The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state.

Physicians who specialize in treating disorders of the RESPIRATORY SYSTEM, especially diagnosing and treating diseases and defects of the lungs and bronchial tree.

A vocabulary database of universal identifiers for laboratory and clinical test results. Its purpose is to facilitate the exchange and pooling of results for clinical care, outcomes management, and research. It is produced by the Regenstrief Institute. (LOINC and RELMA [Internet]. Indianapolis: The Regenstrief Institute; c1995-2001 [cited 2002 Apr 2]. Available from http://www.regenstrief.org/loinc)

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topic

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...


Searches Linking to this Article